The stock of Agenus Inc (NASDAQ:AGEN) is a huge mover today! About 1.05 million shares traded hands. Agenus Inc (NASDAQ:AGEN) has risen 77.64% since March 8, 2016 and is uptrending. It has outperformed by 68.32% the S&P500.
The move comes after 7 months negative chart setup for the $613.06M company. It was reported on Oct, 11 by Barchart.com. We have $6.30 PT which if reached, will make NASDAQ:AGEN worth $55.18 million less.
Analysts await Agenus Inc (NASDAQ:AGEN) to report earnings on October, 25. They expect $-0.30 earnings per share, down 87.50% or $0.14 from last year’s $-0.16 per share. After $-0.24 actual earnings per share reported by Agenus Inc for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
Agenus Inc (NASDAQ:AGEN) Ratings Coverage
Out of 4 analysts covering Agenus (NASDAQ:AGEN), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Agenus has been the topic of 6 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, July 29 by Jefferies. The firm earned “Buy” rating on Friday, March 11 by Maxim Group. The company was downgraded on Tuesday, October 27 by Maxim Group. The stock of Agenus Inc (NASDAQ:AGEN) has “Buy” rating given on Monday, July 27 by MLV. The stock of Agenus Inc (NASDAQ:AGEN) has “Buy” rating given on Wednesday, December 16 by Jefferies. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9.
According to Zacks Investment Research, “Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company’s product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.8 in 2016 Q2. Its down 0.58, from 1.38 in 2016Q1. The ratio turned negative, as 15 funds sold all Agenus Inc shares owned while 26 reduced positions. 7 funds bought stakes while 26 increased positions. They now own 34.68 million shares or 5.72% less from 36.79 million shares in 2016Q1.
Pnc Fin Serv Group accumulated 11,397 shares or 0% of the stock. The Illinois-based Balyasny Asset Management Ltd Com has invested 0% in Agenus Inc (NASDAQ:AGEN). Fisher Asset Management Ltd Com has invested 0% of its portfolio in Agenus Inc (NASDAQ:AGEN). Weiss Multi accumulated 93,312 shares or 0.03% of the stock. State Board Of Administration Of Florida Retirement last reported 21,464 shares in the company. Barclays Public Limited Company reported 222 shares or 0% of all its holdings. Trellus Mngmt Ltd Llc has invested 0.81% of its portfolio in Agenus Inc (NASDAQ:AGEN). Moreover, Assetmark has 0% invested in Agenus Inc (NASDAQ:AGEN) for 19,360 shares. Millennium Management holds 2.95M shares or 0.03% of its portfolio. California State Teachers Retirement System accumulated 0% or 153,258 shares. Valley National Advisers reported 3 shares or 0% of all its holdings. Mount Lucas Ltd Partnership has 0.02% invested in the company for 27,000 shares. Creative Planning last reported 64,171 shares in the company. Moreover, National Planning Corporation has 0% invested in Agenus Inc (NASDAQ:AGEN) for 10,000 shares. Teachers holds 0% or 117,247 shares in its portfolio.
Insider Transactions: Since May 5, 2016, the stock had 3 insider buys, and 0 selling transactions for $513,570 net activity. The insider ARMEN GARO H bought 100,000 shares worth $317,895. 2,250 shares with value of $6,975 were bought by Baysal Ozer on Thursday, May 5. The insider WIINBERG ULF bought $188,700.
AGEN Company Profile
Agenus Inc. (Agenus), incorporated on November 10, 1999, is an immuno-oncology company. The Firm is engaged in discovering and developing treatments for patients with cancer. The Company’s approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Firm has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP) vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. The Firm has programs targeting GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed targets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.